

# RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 Umbelliprenin and Lariciresinol isolated from a long-term-used  
2 herb medicine *Ferula sinkiangensis* induce apoptosis and G0/G1  
3 arresting in gastric cancer cells

4

5

6 Lijing Zhang<sup>a</sup>, Jianyong Si<sup>a</sup>, Guangzhi Li<sup>a</sup>, Xiaojin Li<sup>b</sup>, Leilei Zhang<sup>a</sup>, Li  
7 Gao<sup>a</sup>, Xiaowei Huo<sup>a</sup>, Dongyu Liu<sup>a</sup>, Xiaobo Sun<sup>a</sup>, Li Cao<sup>a\*</sup>

8

9 <sup>a</sup>*Institute of Medicinal Plant Development, Chinese Academy of Medical  
10 Sciences & Peking Union Medical College, Beijing, China*

11 <sup>b</sup>*Xinjiang Institute of Chinese Materia Medica and Ethnodrug, Urumqi,  
12 Xinjiang Province 830002, China*

13

14 Corresponding author

15 Prof. Li Cao

16 E-mail address: lcao@implad.ac.cn.

17 Tel.: +86-010-57833222;

18 Fax: +86-010-57833222

19 Postal address: 151# Malianwa North Road, Haidian District, Beijing  
20 100193, China.

## 21 **Abstract**

22 Effective chemicals isolated from folk medicine are commonly used

23 in the treatment of cancer in Asian countries like China and India.  
24 *Ferula sinkiangensis* K. M. Shen is a traditional herb medicine used  
25 for treating stomach disorders in Xinjiang District of China for  
26 thousands of years. Here, we showed that the growth inhibition effects  
27 of seven compounds first isolated from the seeds of this herb in human  
28 gastric cancer cells and human normal gastric epithelium cells.  
29 Furthermore, we characterized the mechanism of the antiproliferation  
30 effects on gastric cancer cells of the two most specific and effective  
31 compounds: Umbelliprenin (UM) and Lariciresinol (LA). Annexin V/PI  
32 staining demonstrated that UM and LA induce apoptosis in gastric cancer  
33 AGS cells. Loss of mitochondrial membrane potential, upregulation of  
34 proapoptotic protein BAX, and activation of Caspase 3 and PARP  
35 suggested that UM and LA caused the activation of the mitochondrial  
36 apoptosis pathway. Cell cycle analysis showed that UM and LA arrest cell  
37 cycle at G0/G1 phase. Western blot results showed that the expression of  
38 P53, P27, P16 and Rb proteins increased, while the expression of Cyclin  
39 D, Cyclin E, Cdk4 and Cdk2 decreased in cancer cells. Overall, these data  
40 provided evidence that UM and LA have the potential to be used in  
41 cancer therapy.

42

### 43 **Introduction**

44 Gastric cancer is characterized by high mortality rates, and one of the

45 most common malignant cancers worldwide <sup>1</sup>. The median survival of  
46 patients with this metastatic disease is less than one year <sup>2</sup>. The current  
47 treatment therapy for gastric cancer is chemotherapy, but because the side  
48 effects are severe, its application is limited, and effective agents are  
49 urgently needed to improve the prognoses of patients. Although several  
50 agents are under clinical evaluation for gastric cancer such as trastuzumab  
51 and cetuximab <sup>3,4</sup>, the effective response rate of gastric cancer patients to  
52 these treatments is low (only 30-40%) <sup>5</sup>. Recently, natural products for  
53 gastric cancer treatment therapy have obtained increasing attention <sup>6,7</sup>. *F.*  
54 *sinkiangensis* was originally described in the “Medica of the Tang  
55 Dynasty”. As a traditional folk medicine used for the treatment of  
56 stomach disorders in Xinjiang District of China for thousands of years,  
57 the potential value of this herb for treating gastric cancer could not be  
58 ignored <sup>8</sup>. Although there have been studies on the chemical composition  
59 and anti-inflammation activity of this herb <sup>9,10</sup>, the effective components  
60 and mechanism in gastric cancer treatment are still not clear. Our  
61 previous studies have found that a petroleum ether extract of the seeds  
62 showed antitumor activity (Unpublished data). Many compounds,  
63 including steroidal esters and lignin, have been isolated from the seeds  
64 <sup>11,12</sup>. In the present study, we first screened these compounds for the  
65 growth inhibition effect in gastric cancer cells, and then characterized the  
66 possible mechanism. We found that UM and LA were the two most

67 cytotoxic compounds towards gastric cancer cells, and the least cytotoxic  
68 to normal gastric epithelial cells, compared with other compounds. In  
69 addition, the two compounds induced apoptosis and cell cycle arrest in  
70 gastric cancer cells.

## 71 **Materials and Methods**

### 72 **Plant material**

73 The seeds of *F. sinkiangensis* were collected from Yili state, Xinjiang  
74 Uygur Autonomous Region of China, in July 2008, and were identified  
75 by Professor Xiaojin Li. A voucher specimen (No. AP21020720) was  
76 deposited in the Xinjiang Institute of Chinese Materia Medica and  
77 Ethnodrug.

### 78 **Test compounds**

79 The seeds of *F. sinkiangensis* were crushed and refluxed with 95% EtOH  
80 for three times, 2 h for each extraction. Then combined the EtOH extracts,  
81 evaporated under reduced pressure to yield residue, suspended in water  
82 and then partitioned using petroleum ether and dichloromethane. The  
83 dichloromethane extract was further fractionated into ten fractions (A-J)  
84 using silica gel chromatography with CHCl<sub>3</sub>-MeOH (40:1 to 0:1, v/v).  
85 Fraction B was subjected to silica gel column chromatography using a  
86 Sephadex LH-20 column (2.5 × 150 cm) eluting with MeOH, and ten  
87 fractions were obtained. Fraction B-4 and Fraction B-6 were purified by  
88 semi-preparative HPLC to obtain compound 1 (tR = 19 min), compound

89 2 (tR = 21 min); Fraction B-9 was subjected to silica gel column  
90 chromatography eluting with CHCl<sub>3</sub>-MeOH (20:1 to 0:1, v/v), and 12  
91 fractions were obtain (Fraction B-9-1--B-9-12). Fraction B-9-4 was  
92 eluted with CHCl<sub>3</sub>-MeOH-H<sub>2</sub>O (7.5:2.5:1) by preparative scale  
93 chromatography and compound 3 was obtained (Rf =0.6). Then using a  
94 MeOH-H<sub>2</sub>O (47:53) system to obtain compound 4 (tR 23 min) and  
95 compound 5 (tR 33 min) from Fraction B-9-7. Finally, a MeOH-H<sub>2</sub>O  
96 (52:48) system was used to obtain compound 6 (tR 33.7 min) and  
97 compound 7 (tR 37.6 min) from Fraction B-9-11. These compounds were  
98 identified by spectra methods (UV, IR, MS and NMR) and purified by  
99 HPLC (purity > 90%). And compound 1 to compounds 7 were  
100 (7,8-cis-8,8'-trans)-2-4-dihydroxyl-3,5-dimethoxy-lariciresinol(C<sub>20</sub>H<sub>24</sub>O<sub>6</sub>),  
101 Lehmannelol (C<sub>24</sub>H<sub>32</sub>O<sub>4</sub>), Arctigenin (C<sub>21</sub>H<sub>24</sub>O<sub>6</sub>), Quercetin (C<sub>15</sub>H<sub>10</sub>O<sub>7</sub>),  
102 Macrathoin F (C<sub>26</sub>H<sub>26</sub>O<sub>12</sub>), Umbelliprenin (C<sub>24</sub>H<sub>30</sub>O<sub>3</sub>), and Lariciresinol  
103 (C<sub>20</sub>H<sub>24</sub>O<sub>6</sub>). The chromatographic profiles of UM and LA are shown in  
104 supplemental information. These compounds were dissolved as stock  
105 solutions in dimethyl sulfoxide (DMSO) and subjected to serial dilution  
106 with medium before use so the final concentration of DMSO was less  
107 than 1% (v/v).

#### 108 **Reagents and antibodies**

109 Dulbecco's Modified Eagle's Medium (DMEM), Ham's F12 medium,  
110 trypsin, penicillin, streptomycin, fetal bovine serum (FBS) were

111 purchased from Gibco (CA, USA), and 3-(4,5-dimethylthiazol-2-yl)-2,  
112 5-diphenyltetrazolium bromide (MTT), DCFH-DA, DMSO, Hoechst  
113 33342, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-imidacarbocyanine iodide  
114 (JC-1), RNase A, propidium iodide (PI) and trypan blue were purchased  
115 from Sigma-Aldrich (MO, USA). The annexin V-FITC apoptosis  
116 detection kit was obtained from KeyGEN Biotech (Jiangsu, China).  
117 Antibodies against Bax, Bcl-2, Cleaved PARP, Cleaved Caspase-3,  
118 Cyclin D1, Cyclin E, Cdk4, Cdk2, P16 and P27 were purchased from  
119 Santa Cruz Biotechnology (CA, USA). Antibodies against Rb and  $\beta$ -actin  
120 were obtained from Cell Signaling Technology (MA, USA). The cECL  
121 Western Blot Kit was obtained from CoWin Biotech (Beijing, China). All  
122 the chemical reagents were of the highest grade.

123

#### 124 **Cell culture**

125 The human gastric carcinoma cell line AGS and the human prostate  
126 carcinoma cell line PC3 were cultured in Ham's F12 medium containing  
127 10% FBS, 100 U/mL penicillin, and 100  $\mu$ g/mL streptomycin at 37°C  
128 with 5% CO<sub>2</sub>. The human normal gastric epithelial cell line GES-1,  
129 human gastric cancer cell line BGC-823, human cervical carcinoma cell  
130 line HeLa and human lung cancer cell line A549 were cultured in DMEM  
131 supplemented with 10% FBS, 100 U/mL penicillin and 100  $\mu$ g/mL  
132 streptomycin under the same conditions. Cells were passaged at least

133 three times before being used in experiments.

134

### 135 **Animals**

136 Five-week-old male BALB/c nude mice were purchased from Vital River  
137 Laboratories (Beijing, China) and maintained on a 12 h light/dark cycle  
138 in a regulated environment ( $25 \pm 2^\circ\text{C}$ ), with free access to water and food.  
139 The animal protocol was approved by the Animal Ethics Committee at  
140 the Institute of Medicinal Plant Development, Chinese Academy of  
141 Medical Sciences.

142

### 143 **Cell viability and cytotoxicity assays**

144 MTT assay was used to determine cell viability. Cells were seeded in  
145 triplicate in 96-well plates and cultured at  $37^\circ\text{C}$  for 24 h. The cells were  
146 treated with compounds in various concentrations (DMSO, 6.25, 12.5, 25,  
147 50, 100  $\mu\text{M}$ ). After 24 or 48 h treatment, 10  $\mu\text{L}$  MTT was added (5  
148 mg/mL) to each well and incubated for another 4 h. The medium was  
149 then removed and 150  $\mu\text{L}$  DMSO was added. The absorbance was  
150 measured at 570 nm using a Microplate Reader (Bio Tek, USA). Cell  
151 viability was expressed as the ratio of surviving cells in each group to  
152 cells in control group.

153 Trypan blue exclusion was used to examine the number of dead cells in  
154 each group. AGS cells and GES-1 cells were plated in 24-well plates for

155 24 h and then treated with UM or LA (DMSO, 6.25, 12.5, 25, 50, 100  $\mu$ M)  
156 for 24 h. After harvesting, the cells were suspended in phosphate-buffered  
157 saline (PBS) and mixed with 0.4% trypan blue dye solution. The numbers  
158 of viable cells and dead cells were counted using light microscope.

159

### 160 **Hoechst 33342 and AO/EB Staining**

161 AGS cells were cultured in 96-well plates and treated with UM (0, 13.67,  
162 27.34, 54.58  $\mu$ M) or LA (0, 20.82, 41.62, 83.24  $\mu$ M) for 24 h. After  
163 washing with PBS, cells were stained with Hoechst 33342 for 20 min or  
164 stained for 5 min with AO/EB. Nuclear morphology changes were  
165 observed using Image Xpress Micro imaging system (Molecular Devices,  
166 USA).

167

### 168 **Apoptosis analysis**

169 UM and LA induced apoptosis in AGS cells were detected using Annexin  
170 V-FITC/PI apoptosis staining by flow cytometry. Cells were plated and  
171 treated with UM (0, 13.67, 27.34, 54.58  $\mu$ M) or LA (0, 20.82, 41.62,  
172 83.24  $\mu$ M) for 24 h. After harvesting and washing twice with cold PBS,  
173 the cells were incubated with Annexin V and PI in binding buffer at room  
174 temperature for 30 min in the dark. Stained cells were detected and  
175 analyzed using FACS Calibur flow cytometry (Becton Dickinson, USA)

176 <sup>28</sup>. Apoptotic rates were reported as the percentage of apoptotic cells

177 among total cells.

178

### 179 **Detection of Reactive Oxygen Species**

180 ROS production was evaluated by the level of hydrogen peroxide  
181 produced using DCFH-DA by flow cytometry. AGS cells were seeded in  
182 6-well plates and treated with UM (0, 13.67, 27.34, 54.58  $\mu\text{M}$ ) or LA (0,  
183 20.82, 41.62, 83.24  $\mu\text{M}$ ) for 24 h. The cells were then harvested and  
184 incubated with 10  $\mu\text{M}$  of DCFH-DA in serum-free medium for 30 min in  
185 the dark at 37°C. After washing twice with cold PBS, the cells were  
186 analyzed by FACS Calibur flow cytometry to measure ROS levels.

187

### 188 **Mitochondrial membrane potential measurements ( $\Delta\Psi\text{m}$ )**

189 Changes in mitochondrial membrane potential after treatments were  
190 measured by flow cytometry and Image Xpress Micro imaging system  
191 (Molecular Devices, USA) using JC-1. Cells ( $1 \times 10^6$ ) were treated with  
192 UM (0, 13.67, 27.34, 54.58  $\mu\text{M}$ ) or LA (0, 20.82, 41.62, 83.24  $\mu\text{M}$ ) for 24  
193 h. Cells were then harvested and incubated with JC-1 (5  $\mu\text{M}$ ) for 30 min in  
194 the dark at 37 °C. After washing twice with PBS, the cells were analyzed  
195 by flow cytometry and observed using Image Xpress Micro imaging  
196 system.

197

### 198 **Cell cycle analysis**

199 Cell cycle distribution was measured by staining DNA with PI. Cells  
200 ( $1 \times 10^6$ ) were seeded in 6-well plates and treated with UM (0, 13.67,  
201 27.34, 54.58  $\mu\text{M}$ ) or LA (0, 20.82, 41.62, 83.24  $\mu\text{M}$ ) for 24 h. Then cells  
202 were harvested and fixed with 70% ethanol overnight at  $-20\text{ }^\circ\text{C}$ . After  
203 washing twice with PBS, the cells were treated with RNase A for 20 min  
204 and then stained with PI (50 mg/L) for 10 min in the dark<sup>29</sup> at room  
205 temperature. The distribution of each phase in the cell cycle measured by  
206 DNA content was detected using FACS Calibur flow cytometry and  
207 analyzed by ModFit LT 4.0 software.

208

#### 209 **Western blot**

210 AGS cells were exposed to UM (0, 13.67, 27.34, 54.58  $\mu\text{M}$ ) or LA (0,  
211 20.82, 41.62, 83.24  $\mu\text{M}$ ) for 24 h. After collection, cells were lysed in  
212 lysis buffer and protein concentrations were determined by the BCA  
213 method. Protein samples were separated by SDS-PAGE and electrically  
214 transferred onto PVDF membranes. After blocking with 5% non-fat milk  
215 solution for 1 h, the membranes were incubated with primary antibody at  
216  $4^\circ\text{C}$  overnight. Later, the primary antibody was washed with TBST and  
217 incubated with secondary antibody at room temperature for 1 h. Protein  
218 bands were visualized by ECL and the levels of  $\beta$ -actin for each sample  
219 were used as a normalizing control.

220

**221 Effects of UM and LA in tumor xenograft models.**

222 Mice were inoculated subcutaneously with  $1.0 \times 10^6$  BGC-823 human  
223 gastric cancer cells on the right flank. The mice were randomized to six  
224 groups of 8 mice per group the next day. Tumor growth was monitored  
225 and tumor size was measured every day. When the tumor volume reached  
226 approximately 0.3 mm in diameter, drug administration was initiated. UM  
227 and LA were diluted in 0.9% NaCl to the final concentration of 10 mg/kg  
228 or 20 mg/kg in 200  $\mu$ L solution and administered to each mouse. UM and  
229 LA solutions were administered twice a day for 12 days. Mice were then  
230 euthanized and tumors were excised and weighed. Tumor inhibition rate  
231 = (average weight of control group - average weight of treated group) /  
232 average weight of control group  $\times$  100%.

233

**234 Statistical analysis**

235 All data were analyzed by software using IBM SPSS statistics 19.  
236 Statistical significance between groups was defined as \* $p < 0.05$  and \*\* $p$   
237  $< 0.01$ . Results were expressed as mean  $\pm$  SD.

238

**239 Results**

240 **UM and LA preferentially inhibit the growth and induce the death of**  
241 **human gastric cancer AGS cells.**

242 First we studied the anti-proliferative effects of seven compounds isolated

243 from the seeds of *F. sinkiangensis* (**Fig. 1a**) against four human  
244 commonly observed cancer cell lines: stomach (AGS), cervix (HeLa),  
245 lung (A549), prostate (PC3) cancer and human gastric epithelial cell line  
246 GES-1. The concentrations resulting in 50% growth inhibition ( $IC_{50}$ )  
247 were listed in **Table 1**. The  $IC_{50}$  values for the seven compounds varied  
248 for each cell line. A comparison of  $IC_{50}$  values showed that Umbelliprenin  
249 (UM) and Lariciresinol (LA) were the most anti-proliferative compounds  
250 against AGS gastric cancer cell line. In addition, UM and LA were less  
251 cytotoxic to GES-1 cells compared with AGS cells (**Fig. 1b**). Therefore,  
252 we chose UM and LA for further investigation.

253 Trypan blue dye exclusion was used to further evaluate the cytotoxicity of  
254 the two compounds in AGS cells. Cells were exposed to various  
255 concentrations of the two chemicals for 24 h. **Fig. 1c** showed the increase  
256 of dead cells. Together, these data suggested that UM and LA can  
257 preferentially inhibit the growth and induce the death of AGS cells while  
258 being less cytotoxic to GES-1 cells.

259

### 260 **The effects of UM and LA on morphological changes in AGS cells**

261 To elucidate whether UM and LA inhibited AGS cell growth by inducing  
262 apoptosis, we used Hoechst 33342 and AO/EB staining to study the  
263 number of apoptotic cells. Based on  $IC_{50}$  values, we chose 13.67  $\mu\text{M}$  of  
264 UM and 20.82  $\mu\text{M}$  of LA and higher concentrations as treatments for

265 AGS cells. After Hoechst 33342 staining, typical morphological changes  
266 of apoptosis such as condensed chromatin and apoptotic bodies were  
267 observed when cells were exposed to both compounds (**Fig. 2a**). In  
268 contrast, control cells exhibited round nuclei and chromatin were well  
269 distributed. After AO/EB staining, apoptosis cells were observed as  
270 orange nuclei (**Fig. 2b**). These observations indicated that the  
271 proliferation inhibition effect of UM and LA may be related to apoptosis  
272 induction.

273

#### 274 **UM and LA induce apoptosis in AGS cells**

275 To further characterize the apoptosis process of AGS cells induced by  
276 UM and LA, we assessed the numbers of apoptotic cells using Annexin  
277 V-FITC/PI apoptosis staining. After 24 h exposure to UM, the population  
278 of apoptotic cells (AV+/PI- plus AV+/PI+) increased in a dose-dependent  
279 manner (**Fig. 3a**). The cellular apoptotic rates were lower when exposed  
280 to LA (**Fig. 3b**). These results indicate that UM is more effective than LA  
281 in the induction of apoptosis in AGS gastric cancer cells.

282

#### 283 **UM and LA induce the decrease of mitochondrial membrane** 284 **potential (MMP) in AGS cells**

285 Apoptosis is also marked by the decrease of  $\Delta\psi$  and JC-1 is often used as  
286 an indicator to detect  $\Delta\psi$  during apoptosis. The decrease of MMP was

287 measured as the increasing ratio of green-to-red fluorescence. As shown  
288 in **Fig. 4**, JC-1 fluorescence mostly appeared in red in the control group  
289 which indicated that the majority of cells were alive. UM treatment  
290 induced a significant increase of green fluorescence which indicated the  
291 loss of  $\Delta\psi$ . The fluorescence ratios after UM treatment were higher than  
292 LA treatment, which indicated that apoptosis induction is associated with  
293 the loss of  $\Delta\psi$ , with UM is more effective than LA.

294

#### 295 **UM and LA affect the generation of ROS**

296 ROS production was evaluated by the level of hydrogen peroxide  
297 production, using DCFH-DA detected by flow cytometry. After AGS cells  
298 were treated with UM or LA for 24 h, ROS production, as indicated by  
299 fluorescence, increased in a dose-dependent manner (**Fig. 5**). UM  
300 treatment (13.67  $\mu\text{M}$ ) caused a remarkable increase of fluorescence  
301 compared with control group; while the results of LA treatment showed  
302 slower increase of fluorescence respectively. Together, these data showed  
303 that both UM and LA could generate ROS in AGS cells, with UM being  
304 more effective.

305

#### 306 **Effects of UM and LA on apoptosis-related protein expression in** 307 **AGS gastric cancer cells**

308 The Bcl-2 protein family is the key regulator of apoptosis<sup>13</sup>. Our results

309 showed that UM and LA both induced apoptosis in AGS cells. We then  
310 analyzed the protein expression of Bax and Bcl-2 after treating with UM  
311 or LA. Western blot results showed an increase in the level of Bax and a  
312 reduction of Bcl-2 protein after treatment with UM or LA (**Fig. 6a**).  
313 Caspase-3 is an executioner which cleaves a broad spectrum of cellular  
314 target proteins like nuclear PARP, leading to a cell death cascade. We  
315 examined the activation of Caspase-3 and cleaved PARP after exposure to  
316 UM or LA. The results showed a decrease in Cleaved PARP and an  
317 increase in Cleaved Caspase-3 (**Fig. 6a**). Relative protein expression  
318 results are shown in Fig. 6c. Combined with the JC-1 test, these results  
319 indicated that the mitochondrial apoptotic pathway is activated by UM  
320 and LA.

321

### 322 **UM and LA increase G0/G1 arrest of cell cycle in AGS cells**

323 As UM and LA showed significant growth inhibition and effective  
324 apoptosis induction in AGS cells, we investigated their effects on cell  
325 cycle. AGS were treated with UM or LA for 24 h, followed by flow  
326 cytometry analyses. The UM-treated group showed G0/G1 phase arrest  
327 compared with control groups (**Fig. 7a**). Similar results were obtained  
328 when cells were treated with LA, with a slightly lower number of cells  
329 arrested in G0/G1 phase compared with the UM groups ( $76.26 \pm 2.06\%$   
330 for UM and  $71.61 \pm 3.12\%$  for LA) (**Fig. 7b**). The distribution of AGS

331 cells in cell cycle treated by UM or LA are shown in **Fig. 7c** and **Fig. 7d**,  
332 indicating G0/G1 arrest in cell cycle. These results suggested that growth  
333 inhibition and apoptosis induction of UM and LA in AGS gastric cancer  
334 cells is at least partly associated with the induction of G0/G1 arrest in cell  
335 cycle.

336

### 337 **Effects of UM and LA on cell cycle regulation-related protein** 338 **expression in AGS cells**

339 To gain a further understanding about the molecular mechanisms in AGS  
340 cells during cell cycle arrest, we analyzed the effects of UM and LA on  
341 the expression of some major regulatory proteins. **Fig. 6b** showed that  
342 after treatment with UM or LA, the expression of cyclin D1, cyclin E,  
343 CDK2 and CDK4 decreased, while the expression of P27, P16 and Rb  
344 increased. Relative protein expression results are shown in Fig. 6d. These  
345 results suggest that changes of protein expression may play important  
346 roles in G0/G1 arrest of cell cycle in AGS cells.

347

### 348 **UM and LA inhibit tumor growth in BGC-823 tumor xenograft** 349 **models**

350 To assess the antitumor effects of UM and LA in xenograft models,  
351 human gastric cancer cells BGC-823 were inoculated subcutaneously into  
352 nude mice. Five groups of xenograft mice were administered with vehicle

353 (control), 10 mg/kg and 20 mg/kg of UM, 10 mg/kg and 20 mg/kg of LA  
354 twice a day for 12 days and sacrificed at the end. The data showed that  
355 tumors from both UM and LA treatment groups grew slowly than the  
356 control group (**Fig. 8c and Fig. 8d**). In detail, no significant difference of  
357 the tumor volume in each group was observed at the beginning of  
358 treatment. At the end of treatment, tumor inhibition rates of UM were  
359 63.64% (20 mg/kg) or 40.81% (10 mg/kg) and 43.33% (20 mg/kg) or  
360 37.24% (10 mg/kg) in LA treatment groups when compared to the control  
361 group (**Fig. 8a**). The body weights in treatment groups slightly decreased  
362 during the treatment (**Fig. 8b**). Together, these data suggest that UM and  
363 LA effectively inhibit tumor growth.

364

## 365 **Discussion**

366 Gastric cancer is one of the most common malignant diseases, and ranks  
367 second in mortality among all cancers worldwide <sup>14</sup>. Currently,  
368 chemotherapy is used as the primary treatment for this disorder. However,  
369 overall survival rates of patients are low, while the incidences of side  
370 effects are high <sup>15</sup>. Therefore, natural products with the potential for  
371 gastric cancer treatment have gained a lot of attention. *F. sinkiangensis*  
372 (called A-WEI in Mandarin) has been used as an effective medicine in  
373 treating stomach disorders in Xinjiang District of China for thousands of  
374 years <sup>16</sup>. In addition, there have been recent studies on the isolation of

375 compounds from the roots and volatile oil from *F. sinkiangensis*<sup>10,17</sup>.  
376 However, studies on the efficacy and mechanism of the anti-gastric  
377 cancer effects of this valuable medicine have not been reported yet. Our  
378 previous results showed that a petroleum ether extract from the seeds  
379 exhibit antitumor effect *in vivo*. Based on these observations we  
380 performed a further research on the compounds isolated from the seeds.  
381 In the present study, we found seven compounds that show anti-gastric  
382 cancer activity. After screening, we found UM and LA were the most  
383 effective compounds in inhibiting the growth of AGS gastric cancer cells  
384 among the seven compounds tested. We then took these two compounds  
385 as potential therapeutic agents in gastric cancer treatment for further  
386 study.

387 In this study, UM and LA showed the best antitumor activity against AGS  
388 cells with lower toxicity against normal human gastric epithelial cells and  
389 other cancer cell lines, suggesting that UM and LA could be both  
390 effective and specific agents against human gastric cancer cells. Cell  
391 selectivity related with multiple factors such as metabolism and  
392 interaction with specific receptors and tumor microenvironment. There  
393 have been researches on the relations between compounds and biological  
394 targets in their selectivity for cancer cells. For example, a series of  
395 6,7,10-trimethoxy- $\alpha$ -naphthoflavones (4a–o) were synthesized and their  
396 inhibitory potency against cancer cells related with their selectivity for

397 CYP1B1 in human breast adenocarcinoma MCF-7 cell line <sup>18</sup>. And  
398 purine-scaffold compound series showed cell selectivity for different  
399 effects on Grp94 which could regulate intracellular trafficking of Toll-like  
400 receptor 9 <sup>19</sup>. There has also been research on tumor microenvironment  
401 showed that the inhibitory effect of iron chelator DIBI on human and  
402 murine mammary carcinoma and fibrosarcoma cells varies for the change  
403 of tumor microenvironment <sup>20</sup>. Besides these factors the inhibition of  
404 cancer cell proliferation is often associated with cell cycle arrest <sup>21</sup>. The  
405 G1 phase is a key part of the cell cycle. It is involved in the pathogenesis  
406 of many diseases, and also the entry point for many drug therapies <sup>22</sup>. The  
407 few reports on the effects of UM on cell cycle progression demonstrate  
408 that UM arrests the growth of human M4Beu metastatic pigmented  
409 malignant melanoma cells by G1 arrest <sup>23</sup>, whereas no reports on the  
410 effects of LA on cell cycle have been reported. Our results showed that  
411 UM and LA arrest AGS cells in G0/G1 phase, which prevents the  
412 conversion to the S phase and M phase, suggesting one possible  
413 mechanism for cell cycle arrest by UM and LA. Western blot results  
414 showed that cyclin D, cyclin E, CDK4 and CDK2 were down-regulated  
415 after treatments, while CDK inhibitors p27, P16, and downstream Rb  
416 were up-regulated. The CDK inhibitors have been shown to arrest the cell  
417 cycle and inhibit the growth of cancer cells <sup>24</sup>. These results may  
418 therefore provide an additional explanation for the G0/G1 phase arrest

419 induced by UM and LA.

420 Apoptosis induction plays an important role in the inhibition of tumor  
421 cells<sup>25</sup>. Although UM and LA have been shown to induce apoptosis in  
422 some cancer cells<sup>23,26-28</sup>, the effects on anti-gastric cancer cells have not  
423 been reported, and the mechanism is not fully understood. In the present  
424 study, after AO/EB and Hoechst 33342 staining, AV/PI apoptosis  
425 detection, and changes in MMP and ROS tests, we found that both UM  
426 and LA can induce apoptosis in gastric cancer AGS cells. When the cells  
427 were active in the apoptotic pathway, the signal caused the activation of  
428 Caspase-3, which led to apoptosis<sup>29,30</sup>. Western blot analysis showed that  
429 both UM and LA can activate Caspase-3, cleaving the substrate PARP at  
430 the same time. We also found an increase in pro-apoptotic protein Bax  
431 expression and a decrease in anti-apoptotic protein Bcl-2 expression in  
432 AGS cells. An increase in the ratio of Bax/Bcl-2 stimulates the induction  
433 of apoptosis<sup>31</sup>. These results support the roles of Caspase-3 and Bcl-2  
434 family proteins in both UM and LA-induced apoptosis in gastric cancer  
435 cells. The *in vivo* anticancer activity of UM and LA were evaluated in  
436 human gastric cancer BGC-823 xenograft models. The results showed  
437 that both UM and LA can reduce the volume of tumor *in vivo*.

438 Notably, although the IC<sub>50</sub> values of UM and LA in cells varies, the  
439 protein expression levels after treatment by the two compounds showed  
440 no obvious differences. The effects of LA lag behind UM and could be a

441 contributing factor to these results. Thus, the mechanisms involving the  
442 relationships between structure and function are not clear, and further  
443 investigations are necessary.

444 In conclusion, we found UM and LA were the most specific and effective  
445 compounds in the growth inhibition of human gastric cancer AGS cells  
446 among the seven compounds which were first isolated from the seed of *F.*  
447 *sinkiangensis* K. M. Shen. UM and LA could induce apoptosis in AGS  
448 cells with increased Bax/Bcl-2 ratios, the generation of ROS, and the  
449 decrease of MMP. UM and LA could also induce G0/G1 phase arrest in  
450 cell cycle through the regulation of the G0/G1 phase checkpoint proteins.  
451 Therefore, UM and LA could be treated as valuable candidates for further  
452 investigation as possible antitumor treatments for gastric cancer.

453

#### 454 **Acknowledgments**

455 This work was financially supported by the National Natural Science  
456 Foundation of China (No. 81460661) and the Program for Innovative  
457 Research Team in IMPLAD (PIRTI). This work was also supported by  
458 the Ministry of Science and Technology of the People's Republic of  
459 China, and Major Scientific and Technological Special Project for  
460 “Significant New Drugs Formulation” (Grant No. 2012ZX09501001-004  
461 and 2012ZX09301-002-001-026).

462

463 **References**

- 464 1 Y. J. Yu, W. J. Sun, M. D. Lu, F. H. Wang, D. S. Qi, Y. Zhang, P. H. Li, H. Huang, T. You  
465 and Z. Q. Zheng, *World J Gastroentero.*, 2014, **20**, 18413-18419.
- 466 2 R. Siegel, J. Ma, Z. Zou and A. Jemal, *CA-Cancer J Clin.*, 2014, **64**, 9-29.
- 467 3 C. Pinto, F. Fabio, S. Siena, S. Casxinu, L. F. L. Rojas, C. Ceccarelli, V. Mutri, L.  
468 Giannetta, S. Giaquinta, C. Funaioli, R. Berardi, C. Longobardi, E. Piana and A. A.  
469 Martoni, *Ann oncol.*, 2007, **18**, 510-517 (2007).
- 470 4 V. E. Cutsem, *Proc ASCO.*, 2009, **ABSTRACT**, LBA4509.
- 471 5 F. H. Cortés, F. Rivera, I. Alés, A. Márquez, A. Velasco, R. Colomer, C. R. Garcia, J.  
472 Sastre, J. Guerra and C. Gravalos, *Ann oncol.*, 2007, **25**, 4613.
- 473 6 R. Qin, H. Shen, Y. Cao, Y. Fang, H. Li, Q. Chen and W. Xu, *PloS one*, 2013, **8**, e76486.
- 474 7 M. Y. Xu, D. H. Lee, E. J. Joo, K. H. Son and Y. S., *Food chem toxicol.*, 2013, **59**,  
475 703-708.
- 476 8 S. He, and D. Y. Tan, *J Xinjiang Agr Univ.*, 2005, **25**, 1-7.
- 477 9 H. Zhang, and J. Hu, *Chin Pharmacol Bull.*, 1987, **3**, 288-290.
- 478 10 J. R. Yang, Z. An, Z. H. Li, S. Jing and H. L. Qina, *Chem Pharm bull.*, 2006, **54**,  
479 1595-1598.
- 480 11 G. Z. Li, X. J. Li, L. Cao, L. G. Shen, J. Zhu, J. Zhang, J. C. Wang, L. J. Zhang and J. Y.  
481 Si, *Fitoterapia*, 2014, **97**, 247-252.
- 482 12 Y. E. Wang, J. Y. Si, X. J. Li, L. Jiang and J. Zhu, *Mod Chin Med.*, 2011, **13**, 26-28.
- 483 13 W. A. Siddiqui, A. Ahad and H. Ahsan, *Arch Toxicol.*, 2015, **89**, 289-317.
- 484 14 M. B. Piazuero and P. Correa, *Colombia Médica*, 2013, **44**, 192-201.
- 485 15 X. Paoletti, K. Oba, T. Burzykowski, S. Michiels, Y. Ohashi, J. P. Pignon, P. Rougier, J.  
486 Sakamoto, D. Sargent, M. Sasako, E. Van Cutsem and M. Buyse, *Jama*, 2010, **303**,  
487 1729-1737.
- 488 16 C. Tian, L. Q. Xie and G. LI, *Seed*, 2008, **5**, 88-90.
- 489 17 B. Ye, S. Wang and L. Zhang, *Nat Prod Res.*, 2011, **25**, 1161-1170.
- 490 18 J. H. Zhang, Q. Q. Meng, X. Zhang, Q. Cui, W. Zhou and S. S. Li, *J Med. Chem.*, 2015,  
491 **58**, 3534-3547.
- 492 19 H. J. Patel, P. D. Patel, S. O. Ochiana, P. R. Yan, W. L. Sun, M. R. Patel, S. K. Shah, E.  
493 Tramentozzi, J. Brooks, A. Bolaender, L. Shrestha, R. Stephani, P. Finotti, C. Leifer, Z. H.  
494 Li, D. T. Gewirth, T. Taldone and G. Chiosis, *J Med. Chem.*, 2015, **58**, 3922-3943.
- 495 20 M. R. P. Coombs, T. Grant, A. L. Greenshields, D. J. Arsenault, B. E. Holbein and D. W.  
496 Hoskin, *Exp Mol Pathol.*, 2015, **99**, 262-270.
- 497 21 R. Marcotte and E. Wang, *J Gerontol.*, 2002, **57**, B257-269.
- 498 22 M. Narita, S. Nunez, E. Heard, M. Narita, A. W. Lin, S. A. Hearn, D. L. Spector, G. J.  
499 Hannon and S. W. Lowe, *Cell*, 2003, **113**, 703-716.
- 500 23 C. Barthomeuf, S. Lim, M. Iranshahi and P. Chollet, *Phytomedicine*, 2008, **15**, 103-111.
- 501 24 M. Malumbres and M. Barbacid, *Nat Rev: Cancer.*, 2009, **9**, 153-166.
- 502 25 S. W. Lowe and A. W. Lin, *Carcinogenesis*, 2000, **21**, 485-495.
- 503 26 N. Khaghanzadeh, Z. Mojtahedi, M. Ramezani, N. Erfani and A. Ghaderi, *Daru*, 2012, **20**,  
504 69-74.
- 505 27 S. A. Ziai, O. Gholami, M. Iranshahi, A. H. Zamani and M. Jeddi-Tehrani, *Iran J Pharm*

- 506 *Res.*, 2012, **11**, 653-659.
- 507 28 F. Bakar, M. G. Caglayan, F. Onur, S. Nebioglu, S and I. M. Palabiyik, *Anti-cancer Agent*
- 508 *Med.*, 2014, **15**, 336-344.
- 509 29 N. N. Danial, *Clin Cancer Res.*, 2007, **13**, 7254-7263.
- 510 30 T. T. Huang, S. P. Wu, K. Y. Chong, D. M. Ojcius, Y. F. Ko, Y. H. Wu, C. Y. Wu, C. C. Lu,
- 511 J. Martel, J. D. Young and H. C. Lai, *J Ethnopharmacol.*, 2014, **155**, 154-164.
- 512 31 J. Han, P. Tan, Z. Li, Y. Wu, C. Li, Y. Wang, B. Wang, S. Zhao and Y. Liu, *PloS one*, 2014,
- 513 **9**, e86539.

## 514 **Figure Legends**

515 Fig. 1. Active compounds and inhibition effects on cell viability.

516 Chemical structures of seven active compounds isolated from the seed of

517 *Ferula sinkiangensis* (**Fig. 1a**). Effects of UM and LA on the viabilities of

518 human AGS gastric cancer cells AGS (**Fig. 1b**) and human normal gastric

519 epithelial cells GES-1 (**Fig. 1c**). AGS and GES-1 were exposed to various

520 concentrations of the compounds (0, 6.25, 12.5, 25, 50, 100  $\mu$ M) for 24 h

521 or 48 h, followed by the 3-(4,5-dimethylthiazol-2-yl)-2,

522 5-diphenyltetrazolium bromide (MTT) assay. UM and LA suppressed cell

523 viability and induced AGS cells death, while being less cytotoxic to

524 GES-1 cells. The cytotoxic effects of UM and LA on AGS cells was also

525 determined by trypan blue dye exclusion (**Fig. 1d**). The data represent the

526 mean value of three independent experiments and are expressed as means

527  $\pm$  SD. \*\*P < 0.01 was considered statistically significant.

528

529 Fig. 2. Induction of apoptosis by UM and LA in AGS cells. Micrographs

530 show apoptotic cells after treatment with UM or LA at different

531 concentrations and staining by Hoechst 33342 for 24 h (**Fig. 2a**).

532 Micrographs show apoptotic cells treated by UM or LA for 24 h at  
533 different concentrations, followed by staining with AO/EB (**Fig. 2b**).

534

535 Fig. 3. UM and LA induced apoptosis in AGS cells detected by the  
536 Annexin V-FITC/PI staining test.

537 AGS cells were treated with UM (0, 13.67, 27.34, 54.58  $\mu\text{M}$ ) (**Fig. 3a**,  
538 **Fig. 3b**) or LA (0, 20.82, 41.62, 83.24  $\mu\text{M}$ ) (**Fig. 3c**, **Fig. 3d**) for 24 h.

539 DMSO treatment was used as a vehicle control. The apoptotic rates were  
540 determined by Annexin V-FITC/PI staining. Dot-plot graphs show viable  
541 cells (AV-/PI-), necrotic cells (AV-/PI+), early phase apoptotic cells  
542 (AV+/PI-), and late phase apoptotic cells (AV+/PI+). \*P < 0.05 and \*\*P <  
543 0.01 were considered statistically significance.

544

545 Fig. 4. UM and LA induced mitochondrial membrane potential (MMP)  
546 depolarization in AGS cells.

547 AGS cells were cultured in UM (0, 13.67, 27.34, 54.58  $\mu\text{M}$ ) (**Fig. 4a**, **Fig.**  
548 **4b**) or LA (0, 20.82, 41.62, 83.24  $\mu\text{M}$ ) (**Fig. 4c**, **Fig. 4d**) for 24 h. DMSO

549 treatment was used as vehicle control. Cells were then labeled with JC-1  
550 and analyzed by flow cytometry. Results obtained from a representative  
551 experiment are shown (n=3). Statistical significance was \*\*P < 0.01.

552

553 Fig. 5. Effects of UM and LA on the generation of reactive oxygen

554 species (ROS).

555 AGS gastric cancer cells were treated with UM or LA for 24 h. The  
556 increasing level of intracellular ROS after treatment of AGS cells was  
557 measured by flow cytometry after staining with DCFDA (**Fig. 5**). Data  
558 are expressed as percentage of green signals. \*P < 0.05 and \*\* p<0.01 were  
559 considered statistically significant.

560

561 Fig. 6. The effects of UM and LA on the expression of apoptosis-related  
562 proteins (**Fig. 6a** and **Fig. 6c**) and cell cycle-related proteins (**Fig. 6b** and  
563 **Fig. 6d**) were determined by western blot.

564 AGS cells were treated with UM (0, 13.67, 27.34, and 54.58  $\mu$ M) or LA  
565 (0, 20.82, 41.62, and 83.24  $\mu$ M) for 24 h. UM and LA decreased the  
566 expression of Bcl-2 and cleaved PARP, and increased the expression of  
567 Bax and cleaved Caspase-3. Relative expression levels of  
568 apoptosis-related proteins and cell cycle-related proteins are showed in  
569 **Fig. 6c** and **Fig. 6d**.  $\beta$ -actin was used to confirm equal protein loading.  
570 UM and LA decreased the expression of cyclin D1, cyclin E, CDK2 and  
571 CDK 4, with the expression of P27, P16 and Rb increased.  $\beta$ -actin was  
572 used to confirm equal protein loading. \*P < 0.05 and \*\* p<0.01 were  
573 considered statistically significant.

574

575 Fig. 7. Effects of UM and LA on cell cycle progression in AGS cells.

576 Cells were treated by UM (0, 13.67, 27.34, 54.58  $\mu\text{M}$ ) (**Fig. 7b**) or LA (0,  
577 20.82, 41.62, 83.24  $\mu\text{M}$ ) (**Fig. 7d**) for 24 h and then analyzed by flow  
578 cytometry for cell cycle distribution. Cell cycle distributions after UM  
579 (**Fig. 7a**) or LA (**Fig. 7c**) treatment in AGS cells are shown. All tests were  
580 done in triplicate. \*  $P < 0.05$  when compared with the control group.

581

582 Fig. 8. Anti-tumor effects of UM and LA in BGC-823 xenograft tumor  
583 models. UM and LA could inhibit tumor growth in BGC-823 xenograft  
584 models. **Fig. 8a** was the picture of the excised tumors on day 12 in UM  
585 and LA treatment groups. **Fig. 8b** showed the body weight curves of  
586 xenograft mice in UM and LA treatment groups. **Fig. 8c** and **Fig. 8d**  
587 showed the tumor volume growth curve of xenograft models in UM and  
588 LA treatment groups. \* $P < 0.05$  compared with control mice.

589

### 590 **Contributions**

591 L.C. and X.S. designed the experiments; X.L. identified the plant material;  
592 J.Y. and G.Z. isolated compounds. Li.Z., Le.Z., L.G., X.H. and D.L.  
593 performed the experiments; Li.Z. analyzed the data and wrote the  
594 manuscript. All authors reviewed the manuscript and approved it for  
595 submission.

596

### 597 **Competing financial interests**

598 The authors declare no competing financial interests.

599

600 Table 1

601 Cytotoxicity of compounds isolated from the seeds of *Ferula*

602 *sinkiangensis*.

603


Compounds	IC <sub>50</sub> ( $\mu$ M) <sup>a</sup>				
	GES-1	AGS	HeLa	A549	PC3
Umbelliprenin	109.17 $\pm$ 2.07	13.67 $\pm$ 1.73	75.83 $\pm$ 2.66	121.53 $\pm$ 4.41	88.27 $\pm$ 3.76
Lariciresinol	91.98 $\pm$ 1.65	20.82 $\pm$ 2.86	91.36 $\pm$ 4.24	71.28 $\pm$ 2.48	104.69 $\pm$ 3.45
Quercetin	44.51 $\pm$ 2.29	37.62 $\pm$ 2.23	25.05 $\pm$ 2.65	52.54 $\pm$ 1.59	48.87 $\pm$ 3.42
Macrathoin F	62.78 $\pm$ 1.01	68.31 $\pm$ 1.55	119.31 $\pm$ 3.73	77.35 $\pm$ 1.72	95.69 $\pm$ 4.12
Arctigenin	67.82 $\pm$ 1.86	87.76 $\pm$ 3.67	65.23 $\pm$ 1.86	102.58 $\pm$ 3.93	54.43 $\pm$ 1.91
(7,8-cis-8,8'-trans)-2',4'-dihydroxyl-3,5-dimethoxy-lariciresinol	112.92 $\pm$ 3.51	89.01 $\pm$ 3.14	152.84 $\pm$ 1.83	167.29 $\pm$ 4.22	118.68 $\pm$ 4.83
Lehmannolol	79.53 $\pm$ 2.97	156.76 $\pm$ 3.78	182.38 $\pm$ 4.75	>200	187.11 $\pm$ 4.91

604

605 <sup>a</sup> IC<sub>50</sub> is the concentration of compound causing 50% growth inhibition


606 for each cell line. The results represent the mean values of three

607 independent tests.



**Fig. 1.** Active compounds and inhibition effects on cell viability. Chemical structures of seven active compounds isolated from the seed of *Ferula sinkiangensis* (Fig. 1a). Effects of UM and LA on the viabilities of human AGS gastric cancer cells AGS (Fig. 1b) and human normal gastric epithelial cells GES-1 (Fig. 1c). AGS and GES-1 were exposed to various concentrations of the compounds (0, 6.25, 12.5, 25, 50, 100 μM) for 24 h or 48 h, followed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. UM and LA suppressed cell viability and induced AGS cells death, while being less cytotoxic to GES-1 cells. The cytotoxic effects of UM and LA on AGS cells was also determined by trypan blue dye exclusion (Fig. 1d). The data represent the mean value of three independent experiments and are expressed as means ± SD. \*\*P < 0.01 was considered statistically significant.

219x225mm (300 x 300 DPI)



210x366mm (300 x 300 DPI)




Fig. 3. UM and LA induced apoptosis in AGS cells detected by the Annexin V-FITC/PI staining test. AGS cells were treated with UM (0, 13.67, 27.34, 54.58  $\mu\text{M}$ ) (Fig. 3a, Fig. 3b) or LA (0, 20.82, 41.62, 83.24  $\mu\text{M}$ ) (Fig. 3c, Fig. 3d) for 24 h. DMSO treatment was used as a vehicle control. The apoptotic rates were determined by Annexin V-FITC/PI staining. Dot-plot graphs show viable cells (AV-/PI-), necrotic cells (AV-/PI+), early phase apoptotic cells (AV+/PI-), and late phase apoptotic cells (AV+/PI+). \* $P < 0.05$  and \*\* $P < 0.01$  were considered statistically significance.

216x224mm (300 x 300 DPI)




Fig. 4. UM and LA induced mitochondrial membrane potential (MMP) depolarization in AGS cells. AGS cells were cultured in UM (0, 13.67, 27.34, 54.58  $\mu\text{M}$ ) (Fig. 4a, Fig. 4b) or LA (0, 20.82, 41.62, 83.24  $\mu\text{M}$ ) (Fig. 4c, Fig. 4d) for 24 h. DMSO treatment was used as vehicle control. Cells were then labeled with JC-1 and analyzed by flow cytometry. Results obtained from a representative experiment are shown (n=3). Statistical significance was \*\*P < 0.01.

220x229mm (300 x 300 DPI)




Fig. 5. Effects of UM and LA on the generation of reactive oxygen species (ROS). AGS gastric cancer cells were treated with UM or LA for 24 h. The increasing level of intracellular ROS after treatment of AGS cells was measured by flow cytometry after staining with DCFDA (Fig. 5). Data are expressed as percentage of green signals. \* $P < 0.05$  and \*\* $p < 0.01$  were considered statistically significant.

86x35mm (300 x 300 DPI)




Fig. 6. The effects of UM and LA on the expression of apoptosis-related proteins (Fig. 6a and Fig. 6c) and cell cycle-related proteins (Fig. 6b and Fig. 6d) were determined by western blot.

AGS cells were treated with UM (0, 13.67, 27.34, and 54.58 μM) or LA (0, 20.82, 41.62, and 83.24 μM) for 24 h. UM and LA decreased the expression of Bcl-2 and cleaved PARP, and increased the expression of Bax and cleaved Caspase-3. Relative expression levels of apoptosis-related proteins and cell cycle-related proteins are showed in Fig. 6c and Fig. 6d. β-actin was used to confirm equal protein loading. UM and LA decreased the expression of cyclin D1, cyclin E, CDK2 and CDK 4, with the expression of P27, P16 and Rb increased. β-actin was used to confirm equal protein loading. \*P < 0.05 and \*\* p<0.01 were considered statistically significant.

220x182mm (300 x 300 DPI)




Fig. 7. Effects of UM and LA on cell cycle progression in AGS cells. Cells were treated by UM (0, 13.67, 27.34, 54.58  $\mu\text{M}$ ) (Fig. 7b) or LA (0, 20.82, 41.62, 83.24  $\mu\text{M}$ ) (Fig. 7d) for 24 h and then analyzed by flow cytometry for cell cycle distribution. Cell cycle distributions after UM (Fig. 7a) or LA (Fig. 7c) treatment in AGS cells are shown. All tests were done in triplicate. \*  $P < 0.05$  when compared with the control group. 218x221mm (300 x 300 DPI)




Fig. 8. Anti-tumor effects of UM and LA in BGC-823 xenograft tumor models. UM and LA could inhibit tumor growth in BGC-823 xenograft models. Fig. 8a was the picture of the excised tumors on day 12 in UM and LA treatment groups. Fig. 8b showed the body weight curves of xenograft mice in UM and LA treatment groups.

Fig. 8c and Fig. 8d showed the tumor volume growth curve of xenograft models in UM and LA treatment groups. \*P < 0.05 compared with control mice.

212x162mm (300 x 300 DPI)